Centessa Pharmaceuticals could be at the forefront of a leading narcolepsy treatment that can send its shares soaring, according to Morgan Stanley.
One of the company's drugs is ORX750 for the treatment of sleep-wake disorders, including narcolepsy type 1 and 2, or NT1 and NT2.
Additionally, Centessa is developing ORX142 for the treatment of excessive daytime sleepiness, or EDS, in certain neurological, neurodegenerative and psychiatric disorders.
The drug is designed to increase wakefulness, reduce cataplexy and potentially be a novel treatment for narcolepsy type 1.
Given the firm's view of ORX750 as a now de-risked mechanism for treating narcolepsy, Hung modeled a higher peak market share for the treatment in NT1 by 2036.
Persons:
Morgan Stanley, Jeffrey Hung, narcolepsy, Hung
Organizations:
Pharmaceuticals, IH, EDS
Locations:
NT1, NT2